Published in Eur J Cancer Care (Engl) on December 28, 2011
Breast Cancer Survivorship & Work-Related Cognitive Limitation (BCSurvivorship) | NCT02303145
Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol (2012) 1.99
French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3. Support Care Cancer (2012) 1.45
Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS One (2014) 1.45
Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry (2014) 1.30
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin (2014) 1.12
Brain vulnerability to chemotherapy toxicities. Psychooncology (2012) 1.11
The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav (2013) 0.95
Patient reports of cognitive problems are not associated with neuropsychological test performance in bariatric surgery candidates. Surg Obes Relat Dis (2012) 0.80
Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurol (2013) 0.80
Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. Psychooncology (2015) 0.77
Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials. Neurooncol Pract (2015) 0.76
Relationships among psychoneurological symptoms and levels of C-reactive protein over 2 years in women with early-stage breast cancer. Support Care Cancer (2016) 0.75
Can physical activity help to maintain cognitive functioning and psychosocial well-being among breast cancer patients treated with chemotherapy? A randomised controlled trial: study protocol. BMC Public Health (2015) 0.75
What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol (2016) 0.75
The perceptions of Australian oncologists about cognitive changes in cancer survivors. Support Care Cancer (2016) 0.75
Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study. Neuropsychiatr Dis Treat (2017) 0.75
Overexpression of the RON gene in human breast carcinoma. Oncogene (1998) 1.73
Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol (2005) 1.72
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer (1996) 1.51
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol (2006) 1.47
Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol (1994) 1.43
Role of transvaginal sonography in the detection of endometriomata. J Clin Ultrasound (1995) 1.40
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res (1995) 1.38
FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer (1993) 1.37
Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer (1994) 1.36
A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol (1993) 1.30
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat (1996) 1.27
Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: a prospective randomised multicentre trial. Breast (2009) 1.11
Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer (1994) 1.08
Early detection of breast cancer recurrences through periodic follow-up--is it useless? Tumori (1985) 1.04
Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. Br J Cancer (1996) 1.03
Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res (2000) 1.03
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer (1995) 1.02
Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. Eur J Surg Oncol (2011) 1.01
Malignant struma ovarii: a case report of laparoscopic management. Gynecol Oncol (2003) 1.00
Quantification of the risk of post stroke depression: the Italian multicenter observational study DESTRO. Acta Psychiatr Scand (2005) 0.98
Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Res Treat (1988) 0.95
Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric (2009) 0.94
Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol (2006) 0.94
TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res (1996) 0.93
c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer (1991) 0.93
The analgesic effect of crossing the arms. Pain (2011) 0.93
Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg Oncol (2013) 0.91
Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol (1993) 0.91
Laparoscopic identification of pelvic nerves in patients with deep infiltrating endometriosis. Surg Endosc (2004) 0.88
Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. Clin Cancer Res (1999) 0.88
Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol (2008) 0.88
Role of coactivators and corepressors in steroid and nuclear receptor signaling: potential markers of tumor growth and drug sensitivity. Int J Biol Markers (2001) 0.87
Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. Int J Cancer (1998) 0.86
Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. J Clin Lab Anal (1994) 0.86
Chemoresistance in breast tumors. Eur J Gynaecol Oncol (1991) 0.86
Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management. Brain Inj (2001) 0.86
Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res (1994) 0.85
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol (2002) 0.85
The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer. Breast Cancer Res Treat (1999) 0.85
A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol (1999) 0.84
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer (2002) 0.84
Psychiatric symptoms as late onset of Wilson's disease: neuroradiological findings, clinical features and treatment. Ital J Neurol Sci (1999) 0.84
Identification of a possible somatic BRCA1 mutation affecting translation efficiency in an early-onset sporadic breast cancer patient. J Natl Cancer Inst (1998) 0.84
Analysis of complications of cervix carcinoma treated by radiotherapy using the Franco-Italian glossary. Radiother Oncol (1993) 0.84
Quantitative real-time RT-PCR analysis of eight novel estrogen-regulated genes in breast cancer. Int J Biol Markers (2003) 0.83
Fast screening of depression in cancer patients: the effectiveness of the HADS. Eur J Cancer Care (Engl) (2010) 0.83
The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging (2012) 0.83
Role of explicit verbal information in conditioned analgesia. Eur J Pain (2014) 0.82
The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol (2005) 0.82
Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer (2002) 0.82
Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer (2002) 0.81
Transvaginal sonographic tubal patency testing using air and saline solution as contrast media in a routine infertility clinic setting. Ultrasound Obstet Gynecol (1996) 0.80
Post-stroke depression: research methodology of a large multicentre observational study (DESTRO). Neurol Sci (2004) 0.79
Insulin-like growth factor I (IGF-I) serum level modifications during transdermal estradiol treatment in postmenopausal women: a possible bimodal effect depending on basal IGF-I values. Gynecol Endocrinol (1998) 0.79
Sentinel node dissection as definitive treatment for node negative breast cancer patients. Eur J Surg Oncol (2003) 0.79
Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: psychological aspects of physician-patient communication. Ann Oncol (2009) 0.79
Oropharyngeal carcinoma during pregnancy: clinical and psycho-oncological aspects. Acta Otorhinolaryngol Ital (2003) 0.79
Fibromyalgia syndrome: definition and diagnostic aspects. Reumatismo (2008) 0.79
Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial. Breast (2007) 0.78
Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta. Horm Res Paediatr (2011) 0.78
Acute-phase proteins in dogs naturally infected with Leishmania infantum during and after long-term therapy with allopurinol. Vet Res Commun (2007) 0.78
Management of risk of breast carcinoma in postmenopausal women. Endocr Relat Cancer (2004) 0.78
Effect of caffeine on ornithine metabolism in rat brain, liver and kidney. Ital J Biochem (1989) 0.78
Radiosurgical treatment of uterine cervix carcinoma at the 1st Clinic of Obstetrics and Gynecology of the University of Turin, (in the period 1972-1978). Eur J Gynaecol Oncol (1981) 0.78
Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas (2005) 0.78
Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res (1995) 0.78
Breast-conservative surgery with and without radiotherapy in patients aged 55-75 years with early-stage breast cancer: a prospective, randomized, multicenter trial analysis after 108 months of median follow-up. Ann Surg Oncol (2013) 0.78
Use of IgG Avidity test in case definitions of toxoplasmosis in pregnancy. New Microbiol (2004) 0.78
Etiopathogenetic mechanisms of fibromyalgia syndrome. Reumatismo (2008) 0.78
[Aspects of renal function in different ages of adulthood: clearances, tubular function and proximal and distal electrolyte reabsorption]. G Gerontol (1966) 0.77
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. Anticancer Res (1990) 0.77
Transvaginal salpingo-sonography (TSSG) in the evaluation of tubal patency. Acta Eur Fertil (1993) 0.77
Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables. Eur J Gynaecol Oncol (1992) 0.77
HRT and breast cancer risk: a clue for interpreting the available data. Maturitas (1999) 0.77
Isolated hypophyseal tuberculoma: case report. Clin Neuropathol (1989) 0.77
Decreasing arm morbidity by refining axillary surgery in breast cancer. Eur J Surg Oncol (2008) 0.77
The evaluation of the fibromyalgia patients. Reumatismo (2008) 0.76
Lack of association between vigabatrin and impaired cognition. J Int Med Res (1998) 0.76
Is the published literature a reliable guide for deciding between alternative treatments for patients with early cervical cancer? Int J Radiat Oncol Biol Phys (1989) 0.76
Conjugated estrogens and breast cancer risk. Gynecol Endocrinol (1999) 0.76
Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA). Ann N Y Acad Sci (1993) 0.76
Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. Maturitas (1994) 0.76
Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol (1995) 0.76
Clinical outcome and emotional-behavioural status after isolated coronary surgery. Qual Life Res (1992) 0.76
In vitro compared activity of telithromycin and azithromycin against northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. Lett Appl Microbiol (2008) 0.76
Insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 0.75
Hormone replacement therapy and breast cancer risk. JAMA (1996) 0.75
Sentinel lymph node and breast cancer staging: final results of the Turin Multicenter Study. Tumori (2000) 0.75
Brain hydatidosis: report of two cases. J Neurol Neurosurg Psychiatry (1980) 0.75
Term breech trial. Lancet (2001) 0.75
Oral contraceptives and breast cancer. Fertil Steril (1992) 0.75
[Evaluation of the uterine vascular flow by Xe133 in healthy and pathologic pregnancy (preliminary note)]. Minerva Ginecol (1969) 0.75
Misplaced confidences? Fertil Steril (1996) 0.75
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. Gynecol Endocrinol (2007) 0.75
[Medical therapy of cystic mastopathy. A critical review of the literature from 1980 to 1985]. Minerva Ginecol (1986) 0.75